Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1433-8726
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer ; day:16 ; month:3 ; year:2018 ; pages:1-7
World journal of urology ; (16.3.2018), 1-7
- Creator
-
Soria, Francesco
- Contributor
-
Beleni, Andrea I.
D'Andrea, David
Resch, Irene
Gust, Kilian M.
Gontero, Paolo
Shariat, Shahrokh F.
SpringerLink (Online service)
- DOI
-
10.1007/s00345-018-2264-0
- URN
-
urn:nbn:de:1111-201805204167
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:01 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Soria, Francesco
- Beleni, Andrea I.
- D'Andrea, David
- Resch, Irene
- Gust, Kilian M.
- Gontero, Paolo
- Shariat, Shahrokh F.
- SpringerLink (Online service)
Other Objects (12)
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients : Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer
Neoadjuvant therapy in urothelial cancer : New therapies on the horizon
Medical practice and placebo response: an inseparable bond?
Comparison between urothelial and non-urothelial urethral cancer
Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis
ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
Prostatakrebs : Vorbeugung, Diagnose; Therapie
Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer
Focal therapy in intermediate- and high-risk prostate cancer
Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients : Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer
Neoadjuvant therapy in urothelial cancer : New therapies on the horizon
Medical practice and placebo response: an inseparable bond?
Comparison between urothelial and non-urothelial urethral cancer
Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis
ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
Prostatakrebs : Vorbeugung, Diagnose; Therapie
Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer
Focal therapy in intermediate- and high-risk prostate cancer
Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients : Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer
Neoadjuvant therapy in urothelial cancer : New therapies on the horizon
Medical practice and placebo response: an inseparable bond?
Comparison between urothelial and non-urothelial urethral cancer
Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis
ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
Prostatakrebs : Vorbeugung, Diagnose; Therapie
Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer
Focal therapy in intermediate- and high-risk prostate cancer
Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis